Satellos Bioscience Inc. (MSCL.TO)

0.4500 +0.0100 (+2.27%) At close: 03:37PM EDT

Satellos Bioscience Inc.

Royal Bank Plaza
Suite 2800 South Tower 200 Bay Street
Toronto, ON M5J 2J1
Canada

https://satellos.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Francis Gleeson B.B.A. M.B.A	Co-Founder, CEO, President & Director	809.03k	N/A	1955
Ms. Elizabeth Williams CA, CPA	CFO & Corporate Secretary	342.12k	N/A	1978
Dr. Philip Lambert M.A., Ph.D.	Chief Scientific Officer	864.92k	N/A	1969
Ms. Desiree Chan	Chief of Staff	N/A	N/A	N/A
Ms. Courtney Wells	Senior Vice President of Clinical Development Operations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Corporate Governance

Satellos Bioscience Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.